| Asthma
Breo Ellipta vs Qvar RediHaler
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Breo Ellipta vs Qvar Redihaler with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQvar Redihaler has a higher rate of injection site reactions vs Breo Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qvar Redihaler but not Breo Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breo Ellipta
Qvar Redihaler
At A Glance
Oral inhalation
Once daily
ICS/LABA combination
Oral inhalation
Twice daily
Inhaled corticosteroid
Indications
- Chronic Obstructive Airway Disease
- Asthma
- Asthma
Dosing
Chronic Obstructive Airway Disease 1 actuation of BREO ELLIPTA 100/25 mcg once daily by oral inhalation; use a short-acting beta2-agonist for breakthrough symptoms between doses.
Asthma Adults >=18 years: 1 actuation of BREO ELLIPTA 100/25 mcg or 200/25 mcg once daily by oral inhalation; pediatric patients 12-17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily; pediatric patients 5-11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily; maximum dose is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily.
Asthma (adults and adolescents, >=12 years) 40 to 320 mcg twice daily by oral inhalation, approximately 12 hours apart; starting dose 40 to 80 mcg twice daily for those not on an inhaled corticosteroid; maximum 320 mcg twice daily.
Asthma (pediatric, 4 to 11 years) 40 mcg twice daily by oral inhalation, approximately 12 hours apart; may increase to 80 mcg twice daily after 2 weeks if needed; maximum 80 mcg twice daily.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any excipient
- Primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures
- Known hypersensitivity to beclomethasone dipropionate or any ingredient in QVAR REDIHALER
Adverse Reactions
Most common (>=3%) nasopharyngitis, upper respiratory tract infection, oropharyngeal candidiasis, headache, back pain, pneumonia, bronchitis, sinusitis, cough, arthralgia, influenza, pharyngitis, pyrexia
Serious serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia, immunosuppression, hypercorticism, adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, growth effects, glaucoma, cataracts
Postmarketing palpitations, tachycardia, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, nervousness, paradoxical bronchospasm
Most common (>=3%) oral candidiasis, upper respiratory tract infection, nasopharyngitis, oropharyngeal pain, viral upper respiratory tract infection, sinusitis, pharyngitis, headache, pyrexia
Serious oropharyngeal candidiasis, immunosuppression and risk of infections, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing localized Candida infections, aggression, depression, sleep disorders, psychomotor hyperactivity, suicidal ideation (primarily in children), blurred vision, central serous chorioretinopathy
Pharmacology
Breo Ellipta combines fluticasone furoate, a synthetic trifluorinated ICS that inhibits inflammation via glucocorticoid receptor activation, with vilanterol, a LABA that relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors and increasing intracellular cyclic AMP.
Inhaled corticosteroid prodrug; beclomethasone dipropionate is rapidly hydrolyzed to the active monoester 17-monopropionate (17-BMP), which inhibits inflammatory cells (mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and release of inflammatory mediators (histamine, eicosanoids, leukotrienes, cytokines) to reduce airway inflammation in asthma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breo Ellipta
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (10/12)
Qvar Redihaler
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Breo Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Qvar Redihaler
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Breo Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Qvar Redihaler
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breo Ellipta.
No savings programs available for Qvar Redihaler.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Breo ElliptaView full Breo Ellipta profile
Qvar RedihalerView full Qvar Redihaler profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.